| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Chengwen Li | |
| Dawn E Bowles | |||
| Richard Jude Samulski | |||
| Terry van Dyke | |||
| P2860 | cites work | Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism | Q24515072 |
| Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors | Q24529153 | ||
| Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity | Q24529161 | ||
| Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions | Q24531466 | ||
| The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. | Q24533492 | ||
| Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy | Q24535690 | ||
| Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups | Q24623923 | ||
| Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome | Q24671566 | ||
| Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors | Q24682739 | ||
| Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors | Q24683259 | ||
| Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis | Q24684374 | ||
| Structure determination of feline panleukopenia virus empty particles | Q27732038 | ||
| Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis | Q28213353 | ||
| The structure of human parvovirus B19 at 8 A resolution | Q30194136 | ||
| The three-dimensional structure of canine parvovirus and its functional implications | Q30195708 | ||
| Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors | Q30975099 | ||
| Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy | Q31065469 | ||
| Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease | Q31132651 | ||
| In vitro selection of viral vectors with modified tropism: the adeno-associated virus display | Q33187644 | ||
| Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. | Q33193314 | ||
| Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation | Q33604753 | ||
| Cloning and characterization of adeno-associated virus type 5. | Q33641228 | ||
| Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression. | Q45768600 | ||
| AAV as a viral vector for human gene therapy. Generation of recombinant virus | Q45788079 | ||
| Molecular cloning of adeno-associated virus variant genomes and generation of infectious virus by recombination in mammalian cells | Q45796829 | ||
| Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. | Q45854837 | ||
| Vector biophysics: crystal-clear view | Q45855464 | ||
| Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. | Q45864505 | ||
| Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors | Q45867424 | ||
| Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors | Q45870079 | ||
| Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors | Q45873434 | ||
| Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors | Q45879602 | ||
| Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison | Q45880308 | ||
| Expression of human factor VIII by splicing between dimerized AAV vectors | Q45886212 | ||
| rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice | Q45886543 | ||
| Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery | Q45888008 | ||
| How do animal DNA viruses get to the nucleus? | Q46464632 | ||
| Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver | Q48004746 | ||
| Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. | Q50626711 | ||
| Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. | Q52832826 | ||
| Characterization of the DNA of a defective human parvovirus isolated from a genital site | Q64380674 | ||
| Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa | Q40764969 | ||
| Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina | Q40805811 | ||
| Two animal models of retinal degeneration are rescued by recombinant adeno-associated virus-mediated production of FGF-5 and FGF-18. | Q40810201 | ||
| Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector | Q40815049 | ||
| Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells | Q40819088 | ||
| Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease | Q40861090 | ||
| Adeno-associated viral-mediated gene transfer to hepatoma: thymidine kinase/interleukin 2 is more effective in tumor killing in non-ganciclovir (GCV)-treated than in GCV-treated animals | Q40863134 | ||
| Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. | Q40869164 | ||
| Superior gene transfer into solid tumour cells than into human mobilised peripheral blood progenitor cells using helpervirus-free adeno-associated viral vector stocks | Q40921572 | ||
| Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody | Q40969562 | ||
| Assaying for structural variation in the parvovirus capsid and its role in infection | Q41003019 | ||
| Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy | Q41008247 | ||
| Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. | Q41100789 | ||
| Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. | Q41190212 | ||
| A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease | Q41192401 | ||
| Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene | Q41220922 | ||
| Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration | Q41431346 | ||
| Effects of angiogenesis inhibitors on multistage carcinogenesis in mice | Q41648802 | ||
| Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. | Q41722852 | ||
| Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver | Q41753510 | ||
| Generation and characterization of chimeric recombinant AAV vectors | Q41869331 | ||
| Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. | Q42609041 | ||
| Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector | Q43198030 | ||
| Gene therapy restores vision in a canine model of childhood blindness | Q43590733 | ||
| Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. | Q43640355 | ||
| Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. | Q43707952 | ||
| Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors | Q43716886 | ||
| Antitumor effect of an adeno-associated virus vector containing the human interferon-beta gene on experimental intracranial human glioma | Q43723424 | ||
| Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors | Q43740107 | ||
| Real-time single-molecule imaging of the infection pathway of an adeno-associated virus | Q43812869 | ||
| Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector | Q43890874 | ||
| Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes | Q43892747 | ||
| Structure, sequence, and function correlations among parvoviruses | Q43971758 | ||
| Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells | Q43983069 | ||
| Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. | Q44305893 | ||
| Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin | Q44488527 | ||
| Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion | Q44511379 | ||
| Long-term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV-mediated gene replacement therapy | Q44569755 | ||
| Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy | Q44976981 | ||
| Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia | Q45060641 | ||
| Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver | Q45568120 | ||
| Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo | Q45709105 | ||
| Adeno-associated virus vector-mediated transduction in the cat brain | Q45711198 | ||
| Direct comparison of efficiency and stability of gene transfer into the mammalian heart using adeno-associated virus versus adenovirus vectors | Q45711201 | ||
| Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors | Q45721934 | ||
| Structure determination of adeno-associated virus 2: three complete virus particles per asymmetric unit | Q45723313 | ||
| The adeno-associated virus crystal: impact inversely proportional to size | Q45730485 | ||
| Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors | Q45732679 | ||
| Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery | Q45734139 | ||
| Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector | Q45734168 | ||
| Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors | Q45741486 | ||
| Differential expression of a recombinant adeno-associated virus 2 vector in human CD34+ cells and breast cancer cells | Q45742489 | ||
| Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization | Q45742577 | ||
| Transduction and utility of the granulocyte-macrophage colony-stimulating factor gene into monocytes and dendritic cells by adeno-associated virus. | Q45744533 | ||
| Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. | Q45745995 | ||
| Structural analysis of adeno-associated virus transduction circular intermediates. | Q45747262 | ||
| Inducible long-term gene expression in brain with adeno-associated virus gene transfer | Q45751214 | ||
| Functional implications of the structure of the murine parvovirus, minute virus of mice | Q45752812 | ||
| Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration | Q45757316 | ||
| The packaging capacity of adeno-associated virus (AAV) and the potential for wild-type-plus AAV gene therapy vectors | Q45763222 | ||
| Gene therapy against an experimental glioma using adeno-associated virus vectors | Q45766083 | ||
| Quantitative analysis of the packaging capacity of recombinant adeno-associated virus | Q45766162 | ||
| Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. | Q33781976 | ||
| Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers | Q33782809 | ||
| Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts | Q33796712 | ||
| Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer | Q33800432 | ||
| Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer | Q33802811 | ||
| Design and packaging of adeno-associated virus gene targeting vectors | Q33804483 | ||
| CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells | Q33810726 | ||
| Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. | Q33823450 | ||
| Dynamin is required for recombinant adeno-associated virus type 2 infection | Q33825510 | ||
| Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy | Q33846007 | ||
| Insertional mutagenesis of AAV2 capsid and the production of recombinant virus | Q33883772 | ||
| Building a better vector: the manipulation of AAV virions | Q33928283 | ||
| Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination | Q33938668 | ||
| An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease | Q33943954 | ||
| Adeno-associated virus vectors for gene therapy: more pros than cons? | Q34080580 | ||
| The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity | Q34124491 | ||
| Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain | Q34142832 | ||
| Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer | Q34161415 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Clades of Adeno-associated viruses are widely disseminated in human tissues. | Q34193756 | ||
| RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism | Q34194223 | ||
| Identification of PDGFR as a receptor for AAV-5 transduction | Q34264144 | ||
| Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector | Q34348760 | ||
| Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands | Q34354192 | ||
| Gene therapy for hemophilia B: AAV-mediated transfer of the gene for coagulation factor IX to human muscle. | Q34367815 | ||
| Induction of angiogenesis during the transition from hyperplasia to neoplasia | Q34413571 | ||
| Selective and rapid uptake of adeno-associated virus type 2 in brain | Q34471578 | ||
| Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. | Q34486856 | ||
| AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection | Q34486863 | ||
| A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy | Q34779805 | ||
| Gene therapy for sarcoma | Q34994045 | ||
| Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors | Q34998573 | ||
| Adeno-associated virus vectors for therapeutic gene transfer | Q35052563 | ||
| Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. | Q35111738 | ||
| Receptor targeting of adeno-associated virus vectors | Q35165723 | ||
| Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells | Q35228018 | ||
| Adeno-associated viral vectors for retinal gene transfer. | Q35566831 | ||
| Advances in AAV-mediated gene transfer for the treatment of inherited disorders. | Q35628533 | ||
| Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy | Q35799349 | ||
| Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. | Q35892008 | ||
| Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus | Q36159178 | ||
| Sustained correction of bleeding disorder in hemophilia B mice by gene therapy | Q36454880 | ||
| Identification of a heparin-binding motif on adeno-associated virus type 2 capsids | Q36474230 | ||
| Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. | Q36968864 | ||
| Adeno-Associated Viruses | Q38052641 | ||
| Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids | Q38299901 | ||
| Gene therapy vectors based on adeno-associated virus type 1. | Q39550492 | ||
| Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure | Q39589248 | ||
| Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors | Q39589898 | ||
| Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation | Q39602167 | ||
| Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity | Q39686097 | ||
| Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production | Q39698557 | ||
| Characterization of tissue tropism determinants of adeno-associated virus type 1. | Q39700318 | ||
| Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-defici | Q39756843 | ||
| Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding | Q39756934 | ||
| Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers | Q39873805 | ||
| Subcellular compartmentalization of adeno-associated virus type 2 assembly | Q39878164 | ||
| Topoisomerase inhibitors enhance the cytocidal effect of AAV-HSVtk/ganciclovir on head and neck cancer cells | Q40529255 | ||
| AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. | Q40582634 | ||
| Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor | Q40583146 | ||
| Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery | Q40583540 | ||
| Long-term expression of angiostatin suppresses metastatic liver cancer in mice | Q40585480 | ||
| Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy | Q40596034 | ||
| AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo | Q40606232 | ||
| Tumor-specific gene expression using regulatory elements of the glucose transporter isoform 1 gene | Q40606253 | ||
| Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development | Q40616143 | ||
| Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. | Q40639620 | ||
| Delivering antisense telomerase RNA by a hybrid adenovirus/ adeno-associated virus significantly suppresses the malignant phenotype and enhances cell apoptosis of human breast cancer cells | Q40651914 | ||
| Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene | Q40662320 | ||
| Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cell: decrease of oncogenicity and induction of protection. | Q40671525 | ||
| Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo | Q40729476 | ||
| Recombinant AAV-mediated gene delivery using dual vector heterodimerization. | Q40746276 | ||
| Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors | Q40763368 | ||
| P433 | issue | 12 | |
| P921 | main subject | gene therapy | Q213901 |
| vector-borne disease | Q2083837 | ||
| cancer gene therapy | Q124350675 | ||
| P304 | page(s) | 913-925 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | Cancer Gene Therapy | Q15763088 |
| P1476 | title | Adeno-associated virus vectors: potential applications for cancer gene therapy | |
| P478 | volume | 12 |
| Q37148191 | A small regulatory element from chromosome 19 enhances liver-specific gene expression |
| Q34214323 | AAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis model |
| Q37301637 | AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models |
| Q34468330 | AAV2-mediated in vivo immune gene therapy of solid tumours |
| Q36121666 | Acquisition of selective antitumoral effects of recombinant adeno-associated virus by genetically inserting tumor-targeting peptides into capsid proteins |
| Q33305143 | Adeno-associated viral vectors engineered for macrolide-adjustable transgene expression in mammalian cells and mice |
| Q38706321 | Adeno-associated virus (AAV) vectors in cancer gene therapy. |
| Q45417433 | Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice |
| Q34317131 | Adeno-associated virus-mediated gene transfer |
| Q38271253 | Aerosol gene delivery using viral vectors and cationic carriers for in vivo lung cancer therapy |
| Q35549844 | Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice |
| Q40023775 | Augmented transgene expression in transformed cells using a parvoviral hybrid vector |
| Q40263447 | Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy |
| Q35180848 | Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins |
| Q37259636 | DNA vaccination and gene therapy: optimization and delivery for cancer therapy |
| Q33296224 | Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer |
| Q33307618 | Enhanced transduction of colonic cell lines in vitro and the inflamed colon in mice by viral vectors, derived from adeno-associated virus serotype 2, using virus-microbead conjugates bearing lectin |
| Q40060078 | Gene Delivery in Neuro-Oncology |
| Q36591329 | Gene expression and gene therapy imaging |
| Q35661899 | Genetic control of wayward pluripotent stem cells and their progeny after transplantation |
| Q36097231 | Human β-NGF gene transferred to cat corneal endothelial cells |
| Q39331527 | Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry |
| Q41780807 | Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kallistatin |
| Q47260510 | Inhibition of antigen presentation during AAV gene therapy using virus peptides |
| Q33878586 | Intra-articular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus |
| Q45324668 | Lentiviral vectors and adeno-associated virus vectors: useful tools for gene transfer in pain research |
| Q40240165 | Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. |
| Q39519818 | Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia |
| Q38901858 | Niemann-Pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: Clinicopathological correlations and therapeutical implications |
| Q35155679 | Novel cytotoxic vectors based on adeno-associated virus |
| Q36769180 | Oncolytic viruses in cancer therapy |
| Q64094100 | Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression |
| Q39770989 | Recombinant influenza viruses as delivery vectors for hepatis B virus epitopes |
| Q28741003 | Role of protein tyrosine phosphatases in cancer |
| Q40318387 | Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy |
| Q36923812 | Selective killing of Smad4-negative tumor cells via a designed repressor strategy |
| Q45368108 | Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination |
| Q39995055 | Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis |
| Q37356520 | Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide |
| Q24651009 | The status of gene therapy for brain tumors |
| Q37184919 | Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2. |
| Q36780156 | Use of viral vectors for the development of vaccines |
| Q36684458 | Viral gene therapy |
| Q39366114 | Viral gene therapy for breast cancer: progress and challenges |
Search more.